世界の代謝性疾患治療薬市場：市場規模・現状・予測

• 英文タイトル：Global Metabolic Disorder Therapeutics Market Size, Status and Forecast 2019-2025

• レポートコード：QYR9N7545
• 出版社/出版日：QYResearch / 2019年6月14日
※2024年版があります。お問い合わせください。
• レポート形態：英文、PDF、100ページ
• 納品方法：Eメール（受注後２～3営業日）
• 産業分類：医療・製薬・バイオ

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Enterprise License	￥1,154,400 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

当資料は、代謝性疾患治療薬のグローバル市場について調査・分析したレポートで、種類別（リソソーム蓄積症、糖尿病、肥満、遺伝性代謝性疾患、高コレステロール血症）、用途別（経口、非経口、その他）、主要地域別（アメリカ、ヨーロッパ、中国、日本、東南アジア、インド、中南米）の市場規模、市場予測、関連企業情報などが含まれています。

・代謝性疾患治療薬の世界市場規模
・主要企業別市場シェア
・代謝性疾患治療薬の世界市場規模：種類別（リソソーム蓄積症、糖尿病、肥満、遺伝性代謝性疾患、高コレステロール血症）
・代謝性疾患治療薬の世界市場規模：用途別（経口、非経口、その他）
・代謝性疾患治療薬のアメリカ市場規模（種類別、用途別）
・代謝性疾患治療薬のヨーロッパ市場規模（種類別、用途別）
・代謝性疾患治療薬の中国市場規模（種類別、用途別）
・代謝性疾患治療薬の日本市場規模（種類別、用途別）
・代謝性疾患治療薬の東南アジア市場規模（種類別、用途別）
・代謝性疾患治療薬のインド市場規模（種類別、用途別）
・代謝性疾患治療薬の中南米市場規模（種類別、用途別）
・主要企業別分析（企業概要、製品動向、販売量など）
・代謝性疾患治療薬の世界市場予測（2019年-2025年）
・代謝性疾患治療薬の地域別市場予測（2019年-2025年）
...

Increasing demand for one-time therapies for metabolic disorders and rising prevalence of lifestyle diseases are the key factors that are expected to boost the growth of this market.In 2018, the global Metabolic Disorder Therapeutics market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Metabolic Disorder Therapeutics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Metabolic Disorder Therapeutics development in United States, Europe and China.

The key players covered in this study
Novo Nordisk A/S
Sanofi S.A.
Boehringer Ingelheim GmbH
Eli Lilly and Company
Merck KgaA
Amgen, Inc.
AstraZeneca PLC
Actelion Pharmaceuticals Ltd.
Shire PLC
AbbVie, Inc.
Biocon Ltd.
BioMarin Pharmaceutical, Inc.
Bristol-Myers Squibb Company
Cipla, Inc.
CymaBay Therapeutics, Inc.

Market segment by Type, the product can be split into
Lysosomal Storage Diseases
Diabetes
Obesity
Inherited Metabolic Disorders
Hypercholesterolemia

Market segment by Application, split into
Oral
Parenteral
Others

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Metabolic Disorder Therapeutics status, future forecast, growth opportunity, key market and key players.
To present the Metabolic Disorder Therapeutics development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Metabolic Disorder Therapeutics are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

レポート目次

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Metabolic Disorder Therapeutics Market Size Growth Rate by Type (2014-2025)
1.4.2 Lysosomal Storage Diseases
1.4.3 Diabetes
1.4.4 Obesity
1.4.5 Inherited Metabolic Disorders
1.4.6 Hypercholesterolemia
1.5 Market by Application
1.5.1 Global Metabolic Disorder Therapeutics Market Share by Application (2014-2025)
1.5.2 Oral
1.5.3 Parenteral
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Metabolic Disorder Therapeutics Market Size
2.2 Metabolic Disorder Therapeutics Growth Trends by Regions
2.2.1 Metabolic Disorder Therapeutics Market Size by Regions (2014-2025)
2.2.2 Metabolic Disorder Therapeutics Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities

3 Market Share by Key Players
3.1 Metabolic Disorder Therapeutics Market Size by Manufacturers
3.1.1 Global Metabolic Disorder Therapeutics Revenue by Manufacturers (2014-2019)
3.1.2 Global Metabolic Disorder Therapeutics Revenue Market Share by Manufacturers (2014-2019)
3.1.3 Global Metabolic Disorder Therapeutics Market Concentration Ratio (CR5 and HHI)
3.2 Metabolic Disorder Therapeutics Key Players Head office and Area Served
3.3 Key Players Metabolic Disorder Therapeutics Product/Solution/Service
3.4 Date of Enter into Metabolic Disorder Therapeutics Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global Metabolic Disorder Therapeutics Market Size by Type (2014-2019)
4.2 Global Metabolic Disorder Therapeutics Market Size by Application (2014-2019)

5 United States
5.1 United States Metabolic Disorder Therapeutics Market Size (2014-2019)
5.2 Metabolic Disorder Therapeutics Key Players in United States
5.3 United States Metabolic Disorder Therapeutics Market Size by Type
5.4 United States Metabolic Disorder Therapeutics Market Size by Application

6 Europe
6.1 Europe Metabolic Disorder Therapeutics Market Size (2014-2019)
6.2 Metabolic Disorder Therapeutics Key Players in Europe
6.3 Europe Metabolic Disorder Therapeutics Market Size by Type
6.4 Europe Metabolic Disorder Therapeutics Market Size by Application

7 China
7.1 China Metabolic Disorder Therapeutics Market Size (2014-2019)
7.2 Metabolic Disorder Therapeutics Key Players in China
7.3 China Metabolic Disorder Therapeutics Market Size by Type
7.4 China Metabolic Disorder Therapeutics Market Size by Application

8 Japan
8.1 Japan Metabolic Disorder Therapeutics Market Size (2014-2019)
8.2 Metabolic Disorder Therapeutics Key Players in Japan
8.3 Japan Metabolic Disorder Therapeutics Market Size by Type
8.4 Japan Metabolic Disorder Therapeutics Market Size by Application

9 Southeast Asia
9.1 Southeast Asia Metabolic Disorder Therapeutics Market Size (2014-2019)
9.2 Metabolic Disorder Therapeutics Key Players in Southeast Asia
9.3 Southeast Asia Metabolic Disorder Therapeutics Market Size by Type
9.4 Southeast Asia Metabolic Disorder Therapeutics Market Size by Application

10 India
10.1 India Metabolic Disorder Therapeutics Market Size (2014-2019)
10.2 Metabolic Disorder Therapeutics Key Players in India
10.3 India Metabolic Disorder Therapeutics Market Size by Type
10.4 India Metabolic Disorder Therapeutics Market Size by Application

11 Central & South America
11.1 Central & South America Metabolic Disorder Therapeutics Market Size (2014-2019)
11.2 Metabolic Disorder Therapeutics Key Players in Central & South America
11.3 Central & South America Metabolic Disorder Therapeutics Market Size by Type
11.4 Central & South America Metabolic Disorder Therapeutics Market Size by Application

12 International Players Profiles
12.1 Novo Nordisk A/S
12.1.1 Novo Nordisk A/S Company Details
12.1.2 Company Description and Business Overview
12.1.3 Metabolic Disorder Therapeutics Introduction
12.1.4 Novo Nordisk A/S Revenue in Metabolic Disorder Therapeutics Business (2014-2019)
12.1.5 Novo Nordisk A/S Recent Development
12.2 Sanofi S.A.
12.2.1 Sanofi S.A. Company Details
12.2.2 Company Description and Business Overview
12.2.3 Metabolic Disorder Therapeutics Introduction
12.2.4 Sanofi S.A. Revenue in Metabolic Disorder Therapeutics Business (2014-2019)
12.2.5 Sanofi S.A. Recent Development
12.3 Boehringer Ingelheim GmbH
12.3.1 Boehringer Ingelheim GmbH Company Details
12.3.2 Company Description and Business Overview
12.3.3 Metabolic Disorder Therapeutics Introduction
12.3.4 Boehringer Ingelheim GmbH Revenue in Metabolic Disorder Therapeutics Business (2014-2019)
12.3.5 Boehringer Ingelheim GmbH Recent Development
12.4 Eli Lilly and Company
12.4.1 Eli Lilly and Company Company Details
12.4.2 Company Description and Business Overview
12.4.3 Metabolic Disorder Therapeutics Introduction
12.4.4 Eli Lilly and Company Revenue in Metabolic Disorder Therapeutics Business (2014-2019)
12.4.5 Eli Lilly and Company Recent Development
12.5 Merck KgaA
12.5.1 Merck KgaA Company Details
12.5.2 Company Description and Business Overview
12.5.3 Metabolic Disorder Therapeutics Introduction
12.5.4 Merck KgaA Revenue in Metabolic Disorder Therapeutics Business (2014-2019)
12.5.5 Merck KgaA Recent Development
12.6 Amgen, Inc.
12.6.1 Amgen, Inc. Company Details
12.6.2 Company Description and Business Overview
12.6.3 Metabolic Disorder Therapeutics Introduction
12.6.4 Amgen, Inc. Revenue in Metabolic Disorder Therapeutics Business (2014-2019)
12.6.5 Amgen, Inc. Recent Development
12.7 AstraZeneca PLC
12.7.1 AstraZeneca PLC Company Details
12.7.2 Company Description and Business Overview
12.7.3 Metabolic Disorder Therapeutics Introduction
12.7.4 AstraZeneca PLC Revenue in Metabolic Disorder Therapeutics Business (2014-2019)
12.7.5 AstraZeneca PLC Recent Development
12.8 Actelion Pharmaceuticals Ltd.
12.8.1 Actelion Pharmaceuticals Ltd. Company Details
12.8.2 Company Description and Business Overview
12.8.3 Metabolic Disorder Therapeutics Introduction
12.8.4 Actelion Pharmaceuticals Ltd. Revenue in Metabolic Disorder Therapeutics Business (2014-2019)
12.8.5 Actelion Pharmaceuticals Ltd. Recent Development
12.9 Shire PLC
12.9.1 Shire PLC Company Details
12.9.2 Company Description and Business Overview
12.9.3 Metabolic Disorder Therapeutics Introduction
12.9.4 Shire PLC Revenue in Metabolic Disorder Therapeutics Business (2014-2019)
12.9.5 Shire PLC Recent Development
12.10 AbbVie, Inc.
12.10.1 AbbVie, Inc. Company Details
12.10.2 Company Description and Business Overview
12.10.3 Metabolic Disorder Therapeutics Introduction
12.10.4 AbbVie, Inc. Revenue in Metabolic Disorder Therapeutics Business (2014-2019)
12.10.5 AbbVie, Inc. Recent Development
12.11 Biocon Ltd.
12.12 BioMarin Pharmaceutical, Inc.
12.13 Bristol-Myers Squibb Company
12.14 Cipla, Inc.
12.15 CymaBay Therapeutics, Inc.

13 Market Forecast 2019-2025
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2019-2025)
13.10 Market Size Forecast by Application (2019-2025)

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details

List of Tables and Figures

Table Metabolic Disorder Therapeutics Key Market Segments
Table Key Players Metabolic Disorder Therapeutics Covered
Table Global Metabolic Disorder Therapeutics Market Size Growth Rate by Type 2014-2025 (Million US$)
Figure Global Metabolic Disorder Therapeutics Market Size Market Share by Type 2014-2025
Figure Lysosomal Storage Diseases Figures
Table Key Players of Lysosomal Storage Diseases
Figure Diabetes Figures
Table Key Players of Diabetes
Figure Obesity Figures
Table Key Players of Obesity
Figure Inherited Metabolic Disorders Figures
Table Key Players of Inherited Metabolic Disorders
Figure Hypercholesterolemia Figures
Table Key Players of Hypercholesterolemia
Table Global Metabolic Disorder Therapeutics Market Size Growth by Application 2014-2025 (Million US$)
Figure Oral Case Studies
Figure Parenteral Case Studies
Figure Others Case Studies
Figure Metabolic Disorder Therapeutics Report Years Considered
Table Global Metabolic Disorder Therapeutics Market Size 2014-2025 (Million US$)
Figure Global Metabolic Disorder Therapeutics Market Size and Growth Rate 2014-2025 (Million US$)
Table Global Metabolic Disorder Therapeutics Market Size by Regions 2014-2025 (Million US$)
Table Global Metabolic Disorder Therapeutics Market Size by Regions 2014-2019 (Million US$)
Table Global Metabolic Disorder Therapeutics Market Share by Regions 2014-2019
Figure Global Metabolic Disorder Therapeutics Market Share by Regions 2014-2019
Figure Global Metabolic Disorder Therapeutics Market Share by Regions 2019
Table Market Top Trends
Table Global Metabolic Disorder Therapeutics Revenue by Manufacturers (2014-2019) (Million US$)
Table Global Metabolic Disorder Therapeutics Market Share by Manufacturers (2014-2019)
Figure Global Metabolic Disorder Therapeutics Market Share by Manufacturers in 2018
Table Global Metabolic Disorder Therapeutics Manufacturers Market Concentration Ratio (CR5 and HHI)
Table Key Players Head office and Area Served
Table Key Players Metabolic Disorder Therapeutics Product/Solution/Service
Table Date of Enter into Metabolic Disorder Therapeutics Market
Table Mergers & Acquisitions, Expansion Plans
Table Global Metabolic Disorder Therapeutics Market Size by Type (2014-2019) (Million US$)
Table Global Metabolic Disorder Therapeutics Market Size Share by Type (2014-2019)
Figure Global Metabolic Disorder Therapeutics Market Size Market Share by Type (2014-2019)
Table Global Metabolic Disorder Therapeutics Market Size by Application (2014-2019) (Million US$)
Table Global Metabolic Disorder Therapeutics Market Size Share by Application (2014-2019)
Figure Global Metabolic Disorder Therapeutics Market Size Market Share by Application (2014-2019)
Figure Global Metabolic Disorder Therapeutics Revenue Market Share by Application in 2018
Figure United States Metabolic Disorder Therapeutics Market Size 2014-2019 (Million US$)
Table United States Key Players Metabolic Disorder Therapeutics Revenue (2018-2019) (Million US$)
Table United States Key Players Metabolic Disorder Therapeutics Market Share (2018-2019)
Table United States Metabolic Disorder Therapeutics Market Size by Type (2014-2019) (Million US$)
Table United States Metabolic Disorder Therapeutics Market Share by Type (2014-2019)
Table United States Metabolic Disorder Therapeutics Market Size by Application (2014-2019) (Million US$)
Table United States Metabolic Disorder Therapeutics Market Share by Application (2014-2019)
Figure Europe Metabolic Disorder Therapeutics Market Size 2014-2019 (Million US$)
Table Europe Key Players Metabolic Disorder Therapeutics Revenue (2018-2019) (Million US$)
Table Europe Key Players Metabolic Disorder Therapeutics Market Share (2018-2019)
Table Europe Metabolic Disorder Therapeutics Market Size by Type (2014-2019) (Million US$)
Table Europe Metabolic Disorder Therapeutics Market Share by Type (2014-2019)
Table Europe Metabolic Disorder Therapeutics Market Size by Application (2014-2019) (Million US$)
Table Europe Metabolic Disorder Therapeutics Market Share by Application (2014-2019)
Figure China Metabolic Disorder Therapeutics Market Size 2014-2019 (Million US$)
Table China Key Players Metabolic Disorder Therapeutics Revenue (2018-2019) (Million US$)
Table China Key Players Metabolic Disorder Therapeutics Market Share (2018-2019)
Table China Metabolic Disorder Therapeutics Market Size by Type (2014-20189) (Million US$)
Table China Metabolic Disorder Therapeutics Market Share by Type (2014-2019)
Table China Metabolic Disorder Therapeutics Market Size by Application (2014-2019) (Million US$)
Table China Metabolic Disorder Therapeutics Market Share by Application (2014-2019)
Figure Japan Metabolic Disorder Therapeutics Market Size 2014-2019 (Million US$)
Table Japan Key Players Metabolic Disorder Therapeutics Revenue (2018-2019) (Million US$)
Table Japan Key Players Metabolic Disorder Therapeutics Market Share (2018-2019)
Table Japan Metabolic Disorder Therapeutics Market Size by Type (2014-2019) (Million US$)
Table Japan Metabolic Disorder Therapeutics Market Share by Type (2014-2019)
Table Japan Metabolic Disorder Therapeutics Market Size by Application (2014-2019) (Million US$)
Table Japan Metabolic Disorder Therapeutics Market Share by Application (2014-2019)
Figure Southeast Asia Metabolic Disorder Therapeutics Market Size 2014-2019 (Million US$)
Table Southeast Asia Key Players Metabolic Disorder Therapeutics Revenue (2018-2019) (Million US$)
Table Southeast Asia Key Players Metabolic Disorder Therapeutics Market Share (2018-2019)
Table Southeast Asia Metabolic Disorder Therapeutics Market Size by Type (2014-2019) (Million US$)
Table Southeast Asia Metabolic Disorder Therapeutics Market Share by Type (2014-2019)
Table Southeast Asia Metabolic Disorder Therapeutics Market Size by Application (2014-2019) (Million US$)
Table Southeast Asia Metabolic Disorder Therapeutics Market Share by Application (2014-2019)
Figure India Metabolic Disorder Therapeutics Market Size 2014-2019 (Million US$)
Table India Key Players Metabolic Disorder Therapeutics Revenue (2018-2019) (Million US$)
Table India Key Players Metabolic Disorder Therapeutics Market Share (2018-2019)
Table India Metabolic Disorder Therapeutics Market Size by Type (2014-2019) (Million US$)
Table India Metabolic Disorder Therapeutics Market Share by Type (2014-2019)
Table India Metabolic Disorder Therapeutics Market Size by Application (2014-2019) (Million US$)
Table India Metabolic Disorder Therapeutics Market Share by Application (2014-2019)
Figure Central & South America Metabolic Disorder Therapeutics Market Size 2014-2019 (Million US$)
Table Central & South America Key Players Metabolic Disorder Therapeutics Revenue (2018-2019) (Million US$)
Table Central & South America Key Players Metabolic Disorder Therapeutics Market Share (2018-2019)
Table Central & South America Metabolic Disorder Therapeutics Market Size by Type (2014-2019) (Million US$)
Table Central & South America Metabolic Disorder Therapeutics Market Share by Type (2014-2019)
Table Central & South America Metabolic Disorder Therapeutics Market Size by Application (2014-2019) (Million US$)
Table Central & South America Metabolic Disorder Therapeutics Market Share by Application (2014-2019)
Table Novo Nordisk A/S Company Details
Table Novo Nordisk A/S Revenue in Metabolic Disorder Therapeutics Business (2014-2019) (Million US$)
Figure Novo Nordisk A/S Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2014-2019)
Table Novo Nordisk A/S Recent Development
Table Sanofi S.A. Company Details
Table Sanofi S.A. Revenue in Metabolic Disorder Therapeutics Business (2014-2019)(Million US$)
Figure Sanofi S.A. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2014-2019)
Table Sanofi S.A. Recent Development
Table Boehringer Ingelheim GmbH Company Details
Table Boehringer Ingelheim GmbH Revenue in Metabolic Disorder Therapeutics Business (2014-2019)(Million US$)
Figure Boehringer Ingelheim GmbH Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2014-2019)
Table Boehringer Ingelheim GmbH Recent Development
Table Eli Lilly and Company Company Details
Table Eli Lilly and Company Revenue in Metabolic Disorder Therapeutics Business (2014-2019)(Million US$)
Figure Eli Lilly and Company Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2014-2019)
Table Eli Lilly and Company Recent Development
Table Merck KgaA Company Details
Table Merck KgaA Revenue in Metabolic Disorder Therapeutics Business (2014-2019)(Million US$)
Figure Merck KgaA Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2014-2019)
Table Merck KgaA Recent Development
Table Amgen, Inc. Company Details
Table Amgen, Inc. Revenue in Metabolic Disorder Therapeutics Business (2014-2019)(Million US$)
Figure Amgen, Inc. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2014-2019)
Table Amgen, Inc. Recent Development
Table AstraZeneca PLC Company Details
Table AstraZeneca PLC Revenue in Metabolic Disorder Therapeutics Business (2014-2019)(Million US$)
Figure AstraZeneca PLC Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2014-2019)
Table AstraZeneca PLC Recent Development
Table Actelion Pharmaceuticals Ltd. Company Details
Table Actelion Pharmaceuticals Ltd. Revenue in Metabolic Disorder Therapeutics Business (2014-2019)(Million US$)
Figure Actelion Pharmaceuticals Ltd. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2014-2019)
Table Actelion Pharmaceuticals Ltd. Recent Development
Table Shire PLC Company Details
Table Shire PLC Revenue in Metabolic Disorder Therapeutics Business (2014-2019)(Million US$)
Figure Shire PLC Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2014-2019)
Table Shire PLC Recent Development
Table AbbVie, Inc. Company Details
Table AbbVie, Inc. Revenue in Metabolic Disorder Therapeutics Business (2014-2019)(Million US$)
Figure AbbVie, Inc. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2014-2019)
Table AbbVie, Inc. Recent Development
Table Biocon Ltd. Company Details
Table BioMarin Pharmaceutical, Inc. Company Details
Table Bristol-Myers Squibb Company Company Details
Table Cipla, Inc. Company Details
Table CymaBay Therapeutics, Inc. Company Details
Table Global Metabolic Disorder Therapeutics Market Size by Regions (Million US$) 2019-2025
Figure Global Metabolic Disorder Therapeutics Market Size Share by Regions (2019-2025)
Figure Global Metabolic Disorder Therapeutics Market Size Share by Regions in 2025
Figure United States Metabolic Disorder Therapeutics Market Size Forecast (2019-2025)(Million USD)
Figure Europe Metabolic Disorder Therapeutics Market Size Forecast (2019-2025)(Million USD)
Figure China Metabolic Disorder Therapeutics Market Size Forecast (2019-2025)(Million USD)
Figure Japan Metabolic Disorder Therapeutics Market Size Forecast (2019-2025)(Million USD)
Figure Southeast Asia Metabolic Disorder Therapeutics Market Size Forecast (2019-2025)(Million USD)
Figure India Metabolic Disorder Therapeutics Market Size Forecast (2019-2025)(Million USD)
Figure Central & South America Metabolic Disorder Therapeutics Market Size Forecast (2019-2025)(Million USD)
Table Global Metabolic Disorder Therapeutics Market Size by Product (2019-2025) (Million US$)
Figure Global Metabolic Disorder Therapeutics Market Size by Product (2019-2025)
Figure Global Metabolic Disorder Therapeutics Market Size by Product in 2025
Table Global Metabolic Disorder Therapeutics Market Size by Application (2019-2025) (Million US$)
Figure Global Metabolic Disorder Therapeutics Market Size by Application (2019-2025)
Figure Global Metabolic Disorder Therapeutics Market Size by Application in 2025
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources

以下、関連資料のご紹介

世界のペプチドベースの代謝障害治療薬市場：市場規模・現状・予測

Global Peptide Based Metabolic Disorders Therapeutics Market Size, Status and Forecast 2019-2025
QYR9N7788 2019年6月14日 98Pages
当資料は、ペプチドベースの代謝障害治療薬のグローバル市場について調査・分析したレポートで、種類別（エクセナチド、リラグルチド、その他）、用途別（病院薬局、小売薬局、オンライン薬局）、主要地域別（アメリカ、ヨーロッパ、中国、日本、東南アジア、インド、中南米）の市場規模、市場予測、関連企業情報などが含ま...

世界の睡眠障害治療薬市場：市場規模・現状・予測

Global Sleep Disorder Therapeutics Market Size, Status and Forecast 2019-2025
QYR9N8054 2019年6月14日 96Pages
当資料は、睡眠障害治療薬のグローバル市場について調査・分析したレポートで、種類別（不眠症、過度の睡眠、睡眠障害）、用途別（病院薬局、オンライン薬局、小売薬局）、主要地域別（アメリカ、ヨーロッパ、中国、日本、東南アジア、インド、中南米）の市場規模、市場予測、関連企業情報などが含まれています。

世界の季節性情動障害治療薬市場：市場規模・現状・予測

Global Seasonal Affective Disorder Therapeutics Market Size, Status and Forecast 2019-2025
QYR9N8006 2019年6月14日 96Pages
当資料は、季節性情動障害治療薬のグローバル市場について調査・分析したレポートで、種類別（ライトセラピー（光線療法）、薬、その他）、用途別（病院、診療所、その他）、主要地域別（アメリカ、ヨーロッパ、中国、日本、東南アジア、インド、中南米）の市場規模、市場予測、関連企業情報などが含まれています。

世界の大鬱病性障害市場：市場規模・現状・予測

Global Major Depressive Disorder Market Size, Status and Forecast 2019-2025
QYR9N7496 2019年6月14日 95Pages
当資料は、大鬱病性障害のグローバル市場について調査・分析したレポートで、種類別（薬物療法、生物学的療法、瞑想、理学療法、その他）、用途別（25歳未満、25〜45歳、45歳以上）、主要地域別（アメリカ、ヨーロッパ、中国、日本、東南アジア、インド、中南米）の市場規模、市場予測、関連企業情報などが含まれて...

世界の大うつ病性障害市場：市場規模・現状・予測

Global Major Depressive Disorder Therapeutic Market Size, Status and Forecast 2019-2025
QYR9N7497 2019年6月14日 98Pages
当資料は、大うつ病性障害のグローバル市場について調査・分析したレポートで、種類別（薬物療法、生物学的療法、瞑想、理学療法、その他）、用途別（25歳未満、25〜45歳、45歳以上）、主要地域別（アメリカ、ヨーロッパ、中国、日本、東南アジア、インド、中南米）の市場規模、市場予測、関連企業情報などが含まれ...

世界の代謝バイオマーカー試験市場：市場規模・現状・予測

Global Metabolic Biomarker Testing Market Size, Status and Forecast 2019-2025
QYR9N7544 2019年6月14日 96Pages
当資料は、代謝バイオマーカー試験のグローバル市場について調査・分析したレポートで、種類別（分離技術、検出技術、その他）、用途別（創薬、栄養ゲノミクス、毒物学テスト、個別化医療、機能的ゲノミクス）、主要地域別（アメリカ、ヨーロッパ、中国、日本、東南アジア、インド、中南米）の市場規模、市場予測、関連企業...

世界の色素沈着異常症の治療市場：市場規模・現状・予測

Global Hypopigmentation Disorder Treatment Market Size, Status and Forecast 2019-2025
QYR9N7331 2019年6月14日 96Pages
当資料は、色素沈着異常症の治療のグローバル市場について調査・分析したレポートで、種類別（局所用医薬品、レーザー、ケミカルピーリング、マイクロダーマブレーション、その他）、用途別（病院、エステティッククリニック＆皮膚科センター、その他）、主要地域別（アメリカ、ヨーロッパ、中国、日本、東南アジア、インド...

世界の季節性情動障害の治療市場：市場規模・現状・予測

Global Seasonal Affective Disorder Treatment Market Size, Status and Forecast 2019-2025
QYR9N8007 2019年6月14日 98Pages
当資料は、季節性情動障害の治療のグローバル市場について調査・分析したレポートで、種類別（ライトセラピー（光線療法）、薬、心理療法、カウンセリング、その他）、用途別（病院、診療所、医学研究センター、その他）、主要地域別（アメリカ、ヨーロッパ、中国、日本、東南アジア、インド、中南米）の市場規模、市場予測...

世界の色素沈着障害市場：市場規模・現状・予測

Global Pigmentation Disorder Therapeutic Market Size, Status and Forecast 2019-2025
QYR9N7826 2019年6月14日 97Pages
当資料は、色素沈着障害のグローバル市場について調査・分析したレポートで、種類別（薬理学的治療（外用剤、ハイドロキノン、L-アスコルビン酸など）、美容トリートメント（ケミカルピール、レーザー治療、皮膚移植など））、用途別（皮膚科クリニック、ドラッグストアや化粧品店舗、エステティッククリニック、電子商取...

世界の色素沈着障害の治療市場：市場規模・現状・予測

Global Pigmentation Disorder Treatment Market Size, Status and Forecast 2019-2025
QYR9N7827 2019年6月14日 94Pages
当資料は、色素沈着障害の治療のグローバル市場について調査・分析したレポートで、種類別（肝斑、白斑、白皮症、炎症後色素沈着過剰）、用途別（皮膚科クリニック、ドラッグストアや化粧品店舗、エステティッククリニック、電子商取引、その他）、主要地域別（アメリカ、ヨーロッパ、中国、日本、東南アジア、インド、中南...

世界のペプチドベースの代謝障害治療薬市場：市場規模・現状・予測 A metabolic disorder can happen when abnormal chemical reactions in the body alter the normal metabolic process. It can also be defined as inherited single gene anomaly, most of which are autosomal recessive. Peptide therapeutics are used to treat metabolic disorders owing to their stability, effici…
世界のリソソーム蓄積症治療薬市場：市場規模・現状・予測 Lysosomal storage disorders is a group of genetic metabolic diseases caused by enzyme deficiencies in various body cells.The Gaucher's Diseases indication segment is expected to be the most dominant segment in global lysosomal storage diseases therapeutics market. Europe is estimated to be the domin…
世界の代謝バイオマーカー試験市場：市場規模・現状・予測 In medicine, a biomarker is a measurable indicator of the severity or presence of some disease state. More generally a biomarker is anything that can be used as an indicator of a particular disease state or some other physiological state of an organism.Biomarkers are useful in a number of ways, incl…
世界の睡眠障害治療薬市場：市場規模・現状・予測 Sleep disorders result in a lack of deep and restorative sleep.The sleep disorder therapeutics market is expected to witness a high growth over the forecast period owing to the increasing prevalence of sleep disorder in modern times. In 2018, the global Sleep Disorder Therapeutics market size was xx…
世界のリソソーム蓄積症（LSD）市場：市場規模・現状・予測 Lysosomal Storage Disease (LSD) is a genetic disorder that causes various types of nervous system disorders such as clinical abnormalities and cellular dysfunction. There are more than 65 categories of LSD. This disease can be classified into Lipid Metabolism Disorder and Glycoprotein Metabolism Dis…